title: MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
abstract: We report the development of therapy-related early pre-B acute lymphoblastic leukemia in a patient administered a topoisomerase II inhibitor, etoposide, a consolidation therapy agent for acute promyelocytic leukemia. Our case is of interest because of simultaneous relapse of the original leukemia and onset of therapy-related leukemia and relatively rare t(1;11)(p32;q23) translocation with confirmed MLL/AF-1p fusion. This case suggests that careful monitoring for MLL gene rearrangements is necessary after administration of topoisomerase II inhibitors.
authors.affiliation: Division of Hematology, Department of Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan. tsujoka@med.kawasaki-m.ac.jp
authors.forename: Takayuki
authors.initials: T
authors.lastname: Tsujioka
authors.forename: Hideho
authors.initials: H
authors.lastname: Wada
authors.forename: Shunji
authors.initials: S
authors.lastname: Yamamori
authors.forename: Takemi
authors.initials: T
authors.lastname: Otsuki
authors.forename: Sinichiro
authors.initials: S
authors.lastname: Suemori
authors.forename: Toshinori
authors.initials: T
authors.lastname: Kondo
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Nakanishi
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Suetsugu
authors.forename: Makoto
authors.initials: M
authors.lastname: Mikami
authors.forename: Takashi
authors.initials: T
authors.lastname: Sugihara
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics* / Q000648:ultrastructure; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics* / Q000648:ultrastructure; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D017809:Fatal Outcome; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D017404:In Situ Hybridization, Fluorescence; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D051788:Myeloid-Lymphoid Leukemia Protein; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced / Q000235:genetics*; D012008:Recurrence; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic; D014212:Tretinoin / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; C484041:MLL-AF-1p fusion protein, human; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D059005:Topoisomerase II Inhibitors; D003561:Cytarabine; D051788:Myeloid-Lymphoid Leukemia Protein; D014212:Tretinoin; D005047:Etoposide; D008942:Mitoxantrone; D015255:Idarubicin; D003630:Daunorubicin